Palbociclib

Product Description
Polpharma S.A.

-
PL
-
2015On CPHI since
-
4Certificates
-
5000+Employees
Company types
Categories
Specifications
Polpharma S.A.

-
PL
-
2015On CPHI since
-
4Certificates
-
5000+Employees
Company types
More Products from Polpharma S.A. (40)
-
Product Ticagrelor
Ticagrelor
form II
Own process patent to free from nitrosamines
CEP,
US DMF,
EU DMF,
Korean DMF,
Canadian DMF,
Cadifa
DISCLAIMER
Products protected b... -
Product Hydrochlorothiazide
Hydrochlorothiazide
Therapeutic Area: Cardiovascular system • EU DMF available • US DMF no. 17599 available • Japanese DMF available • CEP available
DISCLAIMER
Products protected by valid patents are not offered for sale in countries where the sale of ... -
Product Alendronate sodium
Alendronate Sodium
Trihydrate
> No risk of presence of nitrosamines
> Long experience with commercial manufacturing
> In-house production of the whole product family (Risedronate, Alendronate, Ibandronate)
CEP,
US D... -
Product Pentoxifylline
Pentoxifylline
Form I
Pentoxifylline is a methylxanthine derivative employed to treat intermittent claudication resulting from chronic occlusive arterial disease in the limbs.
Polpharma API • Extensive production experience • Tailor made PSD • Oral & injectab... -
Product Dapagliflozin
Dapagliflozin
amorphous & propanediol
> Cryogenic process
> Green Chemistry
EU DMF
US DMF
Korean DMF
Canadian DMF
DISCLAIMER
Products protected by valid patents are not offer... -
Product Enzaluthamide
Enzalutamide
Anhydrous form R1
CAS No: 915087-33-1
DISCLAIMER
Products protected by valid patents are not offered for sale in countries where the sale of such products constitutes patent infringement. It is within the buyer’s respon... -
Product Apixaban
Apixaban
Polymorphic form N-1
> No risk of nitrosamines > Eco friendly process
> PSD flexibility via micronization
EU DMF,
US DMF,
KOREAN DMF
DISCLAIMER
Products protected by va... -
Product Empagliflozin
Empagliflozin
CRYSTALLINE ANHYDROUS
> Cryogenic process
> Green chemistry
EU DMF,
US DMF,
CHINESE DMF,
KOREAN DMF
DISCLAIMER
Products protected by valid patents... -
Product Baclofen
Baclofen
FORM B
Own innovative process
Global market leader
CEP, US
DMF,
JAPANESE DMF,
KOREAN DMF,
CANADIAN DMF
DISCLAIMER
Products protected by valid patents are not offered for s... -
Product Rivaroxaban
Rivaroxaban
MODIFICATION I
> No risk of presence of nitrosamines
> Innovative crystalization obtaining material of high purity
CEP,
US DMF,
CHINESE DMF,
KOREAN DMF
DISCLAIMER ... -
Product Trametinib
Trametinib
DMSO solvate
Oncology
OEB 5
DISCLAIMER
Products protected by valid patents are not offered for sale in countries where the sale of such products constitutes patent infringement. It is within the buyer’s responsibility and liability... -
Product Zoledronic Acid
Zoledronic Acid
Monohydrate
> No risk of presence of nitrosamines
> Long experience with commercial manufacturing
> In-house production of the whole product family (Risedronate, Alendronate, Ibandronate)
...
Polpharma S.A. resources (5)
-
News CPHI Barcelona 2023: Tackling the Pharma Talent Precipice – Part 2
This year at CPHI Barcelona (24–26 October, 2023) we sat down with C-suite executives and HR professionals to discuss the looming talent crisis in the pharmaceutical industry. With hybrid working persisting post-pandemic and a growing skills gap, how can the pharmaceutical supply chain adjust to a changing labour force? -
Brochure API Product List 2025
Thanks to over 70 years of experience in process development, scale-up and cGMP manufacturing, we support both emerging and established pharmaceutical customers in the development and commercialization of their small molecule API clinical candidates. At our FDA-approved plant located in Central Europe, we provide end-to-end solutions from API development to scale-up allowing smooth process transfer for commercial-scale manufacturing capabilities, with world-class regulatory support. Our strong R&D management team, experienced in the development of chemical processes and complex projects, provides a wide range of solutions to our customers, applying a variety of chemical reactions and conditions, including cryogenic, High Pressure, strong base reactions, and tailor-made particle size distribution modifications. At Polpharma quality comes first. Regular FDA audits prove our reliability and credibility towards business partners around the world.
-
News KiloLab Laboratory: strategic milestone achieved!
KiloLab Laboratory – a development and production in a kilogram scale – has been launched, according to Polpharma API development strategy adopted in 2021. -
Brochure Polpharma API CDMO offer
Thanks to over 70 years of experience in process development, scale-up and cGMP manufacturing, we support both emerging and established pharmaceutical customers in the development and commercialization of their small molecule API clinical candidates. At our FDA-approved plant located in Central Europe, we provide end-to-end solutions from API development to scale-up allowing smooth process transfer for commercial-scale manufacturing capabilities, with world-class regulatory support. Our strong R&D management team, experienced in the development of chemical processes and complex projects, provides a wide range of solutions to our customers, applying a variety of chemical reactions and conditions, including cryogenic, High Pressure, strong base reactions, and tailor-made particle size distribution modifications. At Polpharma quality comes first. Regular FDA audits prove our reliability and credibility towards business partners around the world. -
Video Strategic investment HP API facility
As an EU-based Contract Development and Manufacturing Organization (CDMO) and supplier of active pharmaceutical ingredients, we are advancing our technology capabilities with an Occupational Exposure Limit (OEL) as low as 10 ng/m³ (OEB 6).
Our new capabilities enable GMP and FDA-approved kilo-scale production, offering batch sizes of up to 1.5 kg. This facility features dedicated Analytical Development Laboratories (ADL) and Process Development Laboratories (PDL) to ensure comprehensive support for all production phases. The design incorporates state-of-the-art isolator technology to ensure the safety of both personnel and products, along with industry-standard secondary containment solutions integrated into the infrastructure.
We have secured future capacity expansion through both internal enhancements and external partnerships, with the goal of doubling our production capacity.
Frequently Viewed Together
Recently Visited
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance